New Drug Delivery Systems Study Findings Recently Were Reported by Researchers at Tsinghua University [Controlled Production of Poly (3-Hydroxybutyrate-co-3-Hydroxyhexanoate) (PHBHHx) Nanoparticles for Targeted and Sustained Drug Delivery]
By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Drugs and Therapies have been published. According to news reporting originating in Beijing, People's Republic of China, by NewsRx journalists, research stated, "The ability to control the size and quality of nanoparticles (NPs) during production is critical for their success as a commercial product for clinical applications. Here, we employed a statistical design of experiment approach to identify the key process variables affecting the size of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHx) NPs during production via the solvent evaporation method."
The news reporters obtained a quote from the research from Tsinghua University, "The number of sonication cycles had a standardzed effect on NP size of 55, with sonication power at 25, and PHBHHx concentration at 27 with a combination of these variables having a lower yet significant effect on NP size (p < 0.05). The PHBHHx NPs were stable for at least 7 days with an average polydispersity index of 0.18, a zeta potential of -10 to -40 mV, and an encapsulation efficiency of 63.5 +/- 2%. These data were utilized to produce a prediction graph whereby particles could be produced with sizes ranging from 90 to 205 nm with a low mean curve prediction error of 1.96% for Haperzine-A-loaded NPs. Furthermore, a range of drug encapsulates NPs were produced and showed a sustained release of the encapsulated drug."
According to the news reporters, the research concluded: "This study demonstrates the ability to control the size of drug-loaded particles by manipulation of the production variables, which will allow targeted and controlled drug release to fit a variety of applications."
For more information on this research see: Controlled Production of Poly (3-Hydroxybutyrate-co-3-Hydroxyhexanoate) (PHBHHx) Nanoparticles for Targeted and Sustained Drug Delivery. Journal of Pharmaceutical Sciences, 2014;103(8):2498-2508. Journal of Pharmaceutical Sciences can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Journal of Pharmaceutical Sciences - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1520-6017)
Our news correspondents report that additional information may be obtained by contacting T.R.J. Heathman, Tsinghua Univ, Sch Life Sci, Dept. of Biol Sci & Biotechnol, Beijing 100084, People's Republic of China. Additional authors for this research include W.R. Webb, J.F. Han, Z. Dan, G.Q. Chen, N.R. Forsyth, A.J. El Haj, Z.R.R. Zhang and X. Sun (see also Drugs and Therapies).
Keywords for this news article include: Beijing, People's Republic of China, Asia, 3-Hydroxybutyric Acid, Carboxylic Acids, Drug Delivery Systems, Drugs and Therapies, Emerging Technologies, Hydroxybutyrates, Nanoparticle, Nanotechnology, Organic Chemicals, Therapy
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC